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ABSTRACT
Hodgkin and Reed-Sternberg cells are derived from germinal center B cells. Amplification of identical rearranged
and mutated immunoglobulin genes from different Hodgkin and Reed-Sternberg cells from the same patient also
answered the question of the malignant nature because the clonality—the key criterion of malignancy—of Hodgkin
and Reed-Sternberg cells was hereby shown. In addition, it could be demonstrated that Hodgkin and Reed-
Sternberg cells do not only expand clonally within 1 affected lymph node, but also clonally disseminate in
advanced-stage disease and relapse even after clinical complete remission. Recent publications demonstrate that a
probably small subset of Hodgkin disease exists with T-cell derivation of the respective Hodgkin and Reed-
Sternberg cells. The management of Hodgkin’s disease is undergoing a paradigm shift as a result of very effective
drug regimens that are capable of inducing high remission rates, the use of combined chemoradiotherapy with
involved-field irradiation in early stages, the introduction of effective salvage chemotherapy of relapsed Hodgkin’s
disease with peripheral stem cell transplantation, a better understanding of prognostic factors, economic con-
straints, and a more sensitive realization of the magnitude of late treatment mortality.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Hodgkin’s disease (HD) is one of the most frequent
ymphomas, with an annual incidence rate of 3 to 4 new
ases per 100 000 persons in the Western world. The
allmark of HD is typical large Hodgkin and Reed-
ternberg (HRS) cells, which represent usually 1% of
he cellular inﬁltrate in affected tissues. They are em-
edded in a microenvironment consisting of T cells, B
ells, neutrophils, macrophages, and other cell types. In
he World Health Organization lymphoma classiﬁca-
ion, 5 subtypes of HD are distinguished: namely, nod-
lar sclerosis, mixed cellularity, lymphocyte-rich classi-
al, lymphocyte depletion, and lymphocyte-
redominant HD. On the basis of differences in
ymphoma histology and HRS cell morphology and im-
unophenotype, lymphocyte-predominant HD is con-
idered as a distinct disease, whereas the other 4 subtypes
re grouped together as classic HD.
In lymphocyte-predominant HD, the tumor cells,
hich are called lymphocytic and histiocytic cells, carry
earranged immunoglobulin variable genes—a hallmark c
6f B lymphocytes—and show an immunophenotype typ-
cal for mature B cells, thus demonstrating that they
erive from B cells. It is important to note that the
earranged variable genes of the lymphocytic and histi-
cytic cells carry somatic mutations and often show ev-
dence of ongoing mutational activity during tumor
lone expansion. Such variable gene mutations normally
appen in antigen-activated B cells participating in T
ell–dependent immune responses in the microenviron-
ent of the germinal center by the process of somatic
ypermutation. Therefore, lymphocytic and histiocytic
ells are considered to originate from mutating germinal
enter B cells [1]. The HRS cells in classical HD show a
henotype that does not resemble any normal hemato-
oietic cell type. However, HRS cells from nearly all
ases of classical HD carry clonal and mutated immuno-
lobulin gene rearrangements, thus demonstrating that
lso the HRS cells in classical HD represent transformed
ature B cells. On the basis of the detection of destruc-
ive somatic mutations in approximately a quarter of
ases of classical HD, it is discussed that the HRS cells
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Advances in Hodgkin Disease
Berive from preapoptotic germinal center B cells [2]. A
mall fraction of classical HD, likely 2%, originate
rom T cells.
Recently, gene expression proﬁles of 4 HD-de-
ived cell lines were generated and compared with
orresponding proﬁles from normal mature B cells
nd various types of B–non-Hodgkin’s lymphoma.
ocussing on the expression of B-lineage markers, the
nalysis revealed decreased messenger RNA levels for
early all established B lineage–speciﬁc genes [3].
hese ﬁndings extended earlier studies, which had
lready shown downregulation of several B-cell mark-
rs, such as CD79, Oct-2, and the B cell receptor
BCR). The downregulation of most B cell–speciﬁc
olecules does not involve factors important for an-
igen presentation and interaction with T helper cells
eg, CD40, CD80, and major histocompatibility com-
lex class II), thus suggesting that it is important for
RS cells to retain antigen-presenting capacities.
ransforming Events Involved in HD Pathogenesis
In approximately 40% of cases of classical HD in
he Western world, the HRS cell are infected by
pstein-Barr virus (EBV). Because EBV can immor-
alize B cells in vitro and because the EBV-encoded
atent membrane protein 1, which is expressed by
BV HRS cells, is known to have oncogenic poten-
ial, it is likely that EBV functions as a tumor virus in
D and is casally involved in the pathogenesis of
BV-positive classic HD.
The search for oncogene and tumor-suppressor
ene mutations in HRS cells is hampered by the rarity
f the HRS cells in the tissue. So far, only a few genes
ere analyzed for mutations in HRS cells [1]. Trans-
ocations of the bcl-2 gene were detected only in very
are cases, and no translocations involving the bcl-6
roto-oncogene were identiﬁed. Mutations in the tu-
or-suppressor genes p53 and CD95 occur in only a
ew cases. Because HRS cells mostly lack CD95 mu-
ations but seem to be resistant to CD95-induced
poptosis, other members of the CD95 signaling path-
ay were also analyzed for inactivating mutations, but
o mutations were identiﬁed in the caspase-8, caspase-
0, or Fas-associated death domain (FADD) genes.
The identiﬁcation of constitutive activity of the
uclear factor-B (NF-B) transcription factor, which
lays an important role in the survival of B cells, in the
RS cells of all cases of classic HD prompted studies
f mutations in members of the NF-B signaling
athway [4]. Inactivating mutations in the NF-B in-
ibitors IB and IB were identiﬁed in approxi-
ately 20% and 10% of cases, respectively. Moreover,
enomic ampliﬁcations of the c-Rel proto-oncogene,
member of the NF-B family, are present in approx-mately 30% of cases of classic HD. Thus, it seems t
B & M That several distinct aberrations can contribute to con-
titutive NF-B activity in HRS cells.
berrant Activation of Multiple Signaling
athways in HRS Cells
Numerous studies in the last years revealed dereg-
lated activity of multiple signaling pathways and
ranscription factors in HRS cells of classic HD. As
as already mentioned previously, constitutive NF-B
ctivity is observed in nearly all cases of classical HD
4]. Besides the involvement of transforming events as
otential causes for this activation, NF-B function
ould also be mediated by stimulating CD40 signaling
hrough CD40 ligand–expressing T cells in the mi-
roenvironment or by activating CD30, which is ex-
ressed in all cases of classic HD. The importance of
F-B activity for HRS cell survival has been dem-
nstrated by showing that its inhibition in HD cell
ines induces their apoptosis [4].
The Jak-STAT pathway is the main mediator of
ytokine signaling. In HRS cells, the STAT3 and
TAT6 transcription factors often show constitutive
ctivation. For STAT6, this activation seems to result
rom an autocrine stimulation pathway, because HRS
ells express interleukin (IL)–13 and the IL-13 recep-
or, and inhibition of IL-13 signaling reduced STAT6
ctivity [5]. Inhibiting IL-13 also leads to a reduced
roliferation of HD cell lines, thus indicating a role of
L-13 in HRS cell proliferation [6].
Notch1 is a transmembrane receptor that, upon
inding of ligand, is cleaved and translocates to the
ucleus, where it activates expression of multiple
enes. Notch1 is not expressed by normal B cells, but
t was found at high levels in HRS cells of classic HD.
riggering of HD cell lines by the Notch1 ligand
agged1 induces strong proliferation [7]. Because
agged1 is detectable in vivo in HRS and surrounding
ells, activated Notch1 signaling may contribute to
RS cell proliferation.
A further transcription factor constitutively acti-
ated in HRS cells is AP-1. In HRS cells, AP-1 seems
o be mainly composed of the c-Jun and JunB com-
onents [8]. Inactivation of AP-1 in HD cell lines
ndicates an important role of this factor in the growth
f HRS cells. Whereas c-Jun seems to be upregulated
y an autoregulatory mechanism, JunB is a target of
F-B in HRS cells.
Deregulated activation of receptor tyrosine ki-
ases (RTKs) is frequently involved in cellular trans-
ormation of various malignancies. A recent analysis
evealed aberrant expression and activation of several
TKs platelet derived growth factor receptor alpha
PDGFRA), (DDR2, EPHB1, RON), tropomyosin
elated kinase B (TRKB), and tropomyosin receptor
inase A (TRKA) in HRS cells of classic HD; these
ere most pronounced in the nodular sclerosis sub-
ype [9]. Antibodies detecting phosphotyrosine in sev-
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6ral proteins indeed revealed that the HRS cells in
any cases had increased phosphotyrosine contents,
hus indicating the RTK signal in the HRS cells.
ctivation seems to occur mainly by their ligands in a
aracrine or autocrine fashion. Such coexpression and
ctivation of multiple RTK seems to be unique to HD
mong lymphomas and indicates that this may con-
ribute to HD pathogenesis. It will be important to
dentify the targets of the RTK activity in HRS cells.
he Search for Novel Therapeutic Targets
Although approximately 90% of HD patients can be
ured with current chemotherapy and radiation therapy,
he remaining patients respond poorly to standard treat-
ent. Moreover, the current therapies are associated
ith toxic side effects and a risk for secondary neoplasms.
herefore, there is a need to search for novel therapeutic
pproaches that are less toxic and that are helpful for
reating patients who are not currently curable.
Because the constitutively activated signaling path-
ays discussed previously most likely have important
unctions in the survival and proliferation of HRS
ells, some may become valuable targets for therapeu-
ic intervention. Given the strong indication for a key
ole of NF-B in the survival of HRS cells, inhibiting
F-B seems to be a promising approach. Several
ompounds are currently being developed and tested
hat target NF-B, such as the proteasome inhibitor
ortezomib. Impairing RTK activity may also be an
ttractive target for therapy, because RTK inhibitors
re already in clinical studies for various cancers.
owever, because HRS cells often express multiple
TKs, targeting a single RTK by a speciﬁc inhibitor
ay not be sufﬁcient to induce apoptosis of HRS cells.
There is still little known about the genetic trans-
orming events that cause the generation of HRS cells
nd their rescue from apoptosis. If oncogenes involved in
he pathogenesis of HD are identiﬁed, one may try to
evelop therapeutic strategies to inhibit their function and
hereby induce growth arrest and apoptosis of HRS cells.
Finally, much more is to be learned also regarding
he role of the typical microenvironment in HD. If we
etter understand what role the T cells, macrophages,
osinophils, and other nontumor cells play in support-
ng the growth of the HRS cells or why they fail to
liminate the tumor cells, this may also lead to the
evelopment of novel strategies to cure HD.
URRENT TREATMENT STRATEGIES INCORPORATING
OSITRON EMISSION TOMOGRAPHY IMAGING AND
NTENSITY-MODULATED RADIOTHERAPY IN HD
Over the last 2 decades, and more intensively dur-
ng the past 5 years, the practice of radiotherapy of
D has drastically changed. Small involved ﬁelds re-
laced the large extended ﬁelds such as mantle and s
8nverted Y and allowed multidirectional conﬁguration
f the radiation beam rather than the 2 opposed ﬁeld
pproach. The smaller volume of disease remaining
fter chemotherapy decreased the target size for ra-
iotherapy and provided a better opportunity for de-
reasing the exposure of healthy organs. The small
adiation volumes mandated better identiﬁcation of
argets and improved precision of delivery. Fortu-
ately, reductions in treatment volumes coincided
ith new developments in imaging: the availability of
igh-resolution computed tomographic (CT) and
ositron emission tomography (PET) scanning and
rogress in the planning and delivery of radiotherapy.
f most importance are the wider availability of 3-di-
ensional conformal radiotherapy and the more re-
ent introduction of intensity-modulated radiotherapy
IMRT) that allow precise targeting of the involved
ite with major reduction of radiation to the surround-
ng tissues. Integrating the modern imaging tools into
he planning systems of the new radiation technology
PET-CT simulator) has enhanced accuracy and safer
reatment of challenging volume sites and reirradia-
ion of relapsed sites. More recent developments in
adiotherapy, such as respiratory gating and image-
uided adaptive radiotherapy, may also be relevant to
D and will be discussed. Although the potential
ong-term beneﬁts of this paradigm shift will require
onger observation, it is very likely that the reduction
f healthy tissue exposure, such as breast, heart, and
ungs, will improve the therapeutic ratio.
he Involved Field: Reasons and Implications
f a Major Change in Radiotherapy of HD
For more than 3 decades, the use of extended-ﬁeld
adiotherapy, often encompassing all nodal sites from
he upper neck to the groin, including the spleen, was
he central principle guiding the cure of HD with
adiation alone. This concept is now obsolete. The ra-
iation ﬁeld of today is limited and restricted to the site
f clinical disease, and when the disease volume had been
educed after chemotherapy, it is often limited to the
ew postchemotherapy residual volume [10]. The deﬁ-
ition of involved ﬁeld for different sites is still evolv-
ng, and some radiation oncologists, particularly in
urope, even advocate limiting the ﬁeld to the initially
nvolved individual lymph node(s) and not to the full
ymph node group site.
The reason for the drastic change is quite simple
nd is well supported by solid data. Because radiation
s no longer used as a single agent, there is no need to
reat clinically uninvolved lymph node sites—the sites
hat, if left unirradiated when effective chemotherapy
as not available, were the most prone to relapse.
Several randomized studies have conﬁrmed the ad-
quacy of using involved-ﬁeld radiotherapy (IFRT) in
omparison with extended-ﬁeld radiotherapy and are
ummarized in Table 1. The studies clearly indicate that
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Advances in Hodgkin Disease
Beducing the radiation ﬁeld has not detracted from the
xcellent disease Freedom from treatment failure
FTTF) or relapse-free survival rates (84%-95%) or
verall survival (OS; 92%-94%) in patients with favor-
ble [11] or unfavorable (German Hodgkin’s Disease
tudy Group [GHSG] [12], European Organization for
esearch and Treatment of Cancer [EORTC]/Groupe
’Etudes Des Lymphomes De l’Adulte (GELA) [13,14],
nd Milan [11]) early-stage HD. The detailed analysis of
he GHSG HD8 study demonstrated that a smaller
adiation ﬁeld was associated with a reduction in acute
ide effects and a trend for a lower risk of second malig-
ancies (2.8% versus 4.5%) that may strengthen with a
onger follow-up [12].
Combined-modality therapy not only allows for a
rastic restriction of the irradiated volume, but it also
ermits a meaningful reduction (by up to 50%) in the
ffective prescribed radiation dose. The GHSG stud-
es of combined-modality therapy in patients with
nfavorable early-stage disease indicated that disease
ontrol with 20 Gy was as effective as that with 40 Gy,
rovided that bulky disease sites were irradiated to 40
y [12]. The recently completed GHSG study HD10
or patients with favorable disease randomized pa-
ients to either 20 Gy of IFRT or 30 Gy of IFRT after
short course (2 or 4 cycles) of doxorubicin (Adriamy-
in), bleomycin, vinblastine, and dacarbazine (ABVD)
15]. At a median follow-up of 24 months, the overall
esults are excellent (FFTF of 97%), with no differ-
nce among the 4 arms. The GHSG study of unfa-
orable patients (HD11), with a similar radiotherapy
ose design and a 24-month FFTF of 90%, also sug-
ested that radiation dose reduction is safe [16]. More
ature and detailed results are expected soon. The
ORTC/GELA current H9F trial for favorable pa-
ients is evaluating epirubicin, bleomycine, vinblas-
ine, prednisone (EBVP) 6 to complete remission
CR), followed by either IFRT 36 Gy or involved ﬁeld
adiotherapy (IFRT) 20 Gy. The third arm of patients
ith CR after 6 cycles of EBVP and no radiation was
able 1. Studies Comparing Involved Field Radiation with Extended R
arly-Stage HL
Study Treatm
ilan (133 patients) [2] ABVD (4)
ABVD (4)
HSG HD8 (1064 patients) [3] COPP/AB
COPP/AB
ORTC/GELA H8U (995 patients) [4] MOPP/AB
MOPP/AB
MOPP/AB
FS indicates relapse-free survival; HL, Hodgkin’s lymphoma; EFR
subtotal lymphoid irradiation; NS, not signiﬁcant.losed early because of an excessive number of re- s
B & M Tapses. The combined-modality arms remained open
ntil the study ended.
The conversion from large multisite radiation ﬁelds
o a smaller and better deﬁned radiation ﬁeld allowed
lso for accurate conformal radiation therapy. The large
elds of the past limited the radiation technique to 2
imple opposed anterior and posterior ﬁelds. The con-
ersion to smaller and better deﬁned radiation volumes
llowed the use of more conformal radiation therapy,
ased on better imaging, computerized planning pro-
rams, and, when indicated, advanced tools such as
MRT. Modern breakthroughs in radiotherapy technol-
gy can now be implemented in HD to increase accu-
acy even further, avoid healthy organ irradiation, and
hus improve the therapeutic ratio [17].
The only clear indication to use radiation alone in
D is in early-stage lymphocyte predominance HD.
et this rare subtype of HD does not require exten-
ive-ﬁeld radiotherapy. The disease is commonly lim-
ted to 1 peripheral site (neck, axilla, or groin), and
nvolvement of the mediastinum is extremely rare.
he treatment recommendations for lymphocyte pre-
ominance HD differ markedly from those for classic
D [18]. Chemotherapy is not indicated for early-
tage disease, and it should be emphasized that even if
egional radiation ﬁelds are selected, the uninvolved
ediastinum should not be irradiated, thus avoiding
he site most prone to radiation-related short- and long-
erm side effects. Although there has not been a study
hat compared extended-ﬁeld radiotherapy (commonly
sed in the past) with IFRT, retrospective data suggest
hat IFRT is adequate [19]. The radiation dose recom-
ended is between 30 to 36 Gy, with an optional
dditional boost of 4 Gy to a (rare) bulky site.
Although the decreases in radiation ﬁelds and
oses described previously maintained disease control
ates that are difﬁcult to top, the concern regarding
he contribution of radiation to long-term complica-
ions and late mortality from second tumors and cor-
nary heart disease still prevails [20]. However, it
in Combined-Modality Programs for Favorable and Unfavorable
gimens FFTF or RFS OS (y)
I 97% 93% (5)
T 94% 94%
NS NS
 EFRT 86% 91% (5)
 IFRT 84% 92%
NS NS
IFRT 94% 90% (4)
IFRT 95% 95%
STLI 96% 93%
NS NS
nded-ﬁeld radiotherapy; IFRT, involved-ﬁeld radiotherapy; STLI,adiation
ent Re
 STL
 IFR
VD (4)
VD (4)
V (6) 
V (4) 
V (4) 
T, extehould be recognized that data regarding these late
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7omplications are generated from series of patients
ured of HD during the 1960s and 1970s by full-dose
xtended-ﬁeld radiation alone [21]. It will take at least
nother decade to assess the risk from low-dose mi-
iradiotherapy. Early data suggest that it is likely to be
arkedly reduced [10,11]. It was also clearly estab-
ished by international case-control studies that the
isk of both breast cancer and lung cancer is radiation
ose dependent, and it is predictable that if most of
he organ is not exposed, the total risk is reduced
22-24]. Here, the change to IFRT is critical [25].
his could be illustrated in reference to the radiation-
elated risk of breast cancer in young women. By using
he extended mantle ﬁeld of the past, a substantial
mount of breast tissue has been exposed to either the
ull prescribed dose or to an attenuated dose (at the
eld margins or under the lung shields) in almost all
omen irradiated for HD. Most breast exposure in
he mantle era resulted from the radiation of the
xillae (65% of tumors in this study developed in the
uter part of the breast) [22] and, to a lesser extent,
rom wide mediastinal and hilar irradiation. Approxi-
ately two thirds of women with early-stage HD do
ot require radiation of the axillae, and additional
rotection to the upper and medial aspects of the
reast could be provided by further reducing the ﬁeld
ize by using careful CT-based planning, which usu-
lly allows for smaller mediastinal volumes, especially
fter chemotherapy. At the same time, omitting radio-
herapy altogether not only requires longer and po-
entially toxic chemotherapy, but it also results in
nferior and worrisome outcomes, as several recent
andomized studies have documented [26-28].
odern Involved-Field Treatment Planning: New
ptions, New Tools
The conversion from large multisite radiation
elds to a smaller and better deﬁned small radiation
eld with reduced uncertainty margins mandated ac-
urate identiﬁcation of the involved volume and opti-
al and consistent radiation targeting. At the same
ime, it allowed the option of 3-dimensional confor-
al radiation therapy. The old extensive radiation
elds of the past, such as mantle or inverted Y, in-
luded multiple sites at various depths (from the body
urface), and each site had different limitations of
ccess and tolerance of healthy tissue. The only way to
nclude these sites in 1 radiation ﬁeld (and, thus, avoid
ndesired overlaps and gaps when radiation ﬁelds
ere matched) was to treat the entire ﬁeld from only
opposed directions: anterior and posterior. This
echnique ensured the inclusion of most lymph nodes
n 1 ﬁeld, yet it also resulted in the exposure of large
olumes of healthy organs (eg, heart, lungs, breasts,
nd spinal cord) to the full prescribed radiation dose.
ecause the notion of treating large areas of involved
nd uninvolved areas has changed in favor of treating p
0nly the involved lymph node group, new options of
ore conformal radiotherapy have opened up. When
he target is limited, a multiple noncoplanar beam
pproach is possible.
Over the last decade, the imaging of HD has
arkedly improved. Fast high-resolution CT scanners
nd ﬂuorodeoxyglucose PET scanning are invaluable
or identiﬁcation of involved sites. New technology
llowed integration of the 2 scanners (PET and CT)
nd has provided an incremental advantage to radio-
herapy planning that has already integrated CT sim-
lation as a standard planning tool. Software that
llows simultaneous treatment planning on CT im-
ges and PET images or, even better, the new gener-
tion of PET-CT simulator equipment has upgraded
ur ability to precisely outline tumor volumes while
he patient is in the radiation treatment position. De-
endable immobilization devices are used to ensure
onsistency throughout the treatment course of frac-
ionated radiotherapy. New experimental tools such as
espiratory gating and online image-guided adaptive
adiotherapy may also have a role in the treatment of
elected cases of HD in the future.
The most important upgrade in radiation oncol-
gy of recent years has been the development and
mplementation of IMRT. IMRT incorporated new
lanning concepts with powerful computing and re-
uired a new generation of linear accelerators equipped
ith computer-controlled dynamic multileaf collimators
o allow accurate planning of challenging targets that lie
ery close to critical healthy organs. We have found
hat IMRT is a valuable tool in planning certain large
horacic volumes and is critical for reirradiating re-
apsed disease as part of a salvage program [17].
The change in the lymphoma radiotherapy para-
igm thus coincided with substantial improvements in
maging and treatment-planning technology that have
evolutionized the ﬁeld of radiotherapy over the last 15
ears. IMRT allows for accurately enveloping the tumor
ith either a homogenous radiation dose (“sculpting”) or
elivering higher doses to predetermined areas in the
umor volume (“painting”). The end result of this new
odality is highly accurate treatment with maximal
paring of healthy tissues.
REATMENT OF ADVANCED AND RELAPSED HD
dvanced HD
Up to the middle of the last century, patients with
dvanced stages of HD were incurable. With the ad-
ent of more effective drugs used early in childhood
eukemia, Moxley et al. [29] at the National Cancer
nstitute were the pioneers who paved the road for the
ncredible success of modern chemotherapy in oncol-
gy, with a 50% cure rate for advanced-stage HD
atients, purely with the drug combination MOPP
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Advances in Hodgkin Disease
Bmechlorethamine, vincristine [Oncovin], procarba-
ine, and prednisone).
Despite the great accomplishments with MOPP
nd MOPP-like regimens, there were major obstacles:
1) 15% to 30% of the patients did not reach a CR,
nd only approximately 50% of patients could be
ured, and (2) MOPP had signiﬁcant acute toxicity
nd an increased risk of sterility and acute leukemia
ecause of the alkylating agents.
In 1975, Bonadonna et al. [30] introduced the
BVD regimen in an attempt to develop a regimen
or patients who had experienced treatment failure
fter MOPP. Vinblastine had demonstrated high ac-
ivity as a single agent and lacked cross-resistance with
incristine in human tumors. Both doxorubicin and
leomycin were very active drugs and showed objective
esponses in approximately 50% of patients. Dacarba-
ine was added because it was active as a single agent and
lso showed synergism with doxorubicin.
The results of prospective multicenter trials using
he traditional standard regimens MOPP or ABVD
r alternating, sequential, or hybrid combinations of
hese 2 very effective, non–cross-resistant drug regi-
ens, mostly assisted by additive radiotherapy have
hown satisfactory CR rates (up to 80%-90%). How-
ver, the failure-free survival and OS rates at 5 years
ere only 65% to 70% and 75% to 85%, respectively.
he pivotal Cancer and Leukemia Group B trial in
dvanced HD, which compared MOPP, ABVD, and
lternating MOPP/ABVD without additive radiother-
py, showed equal therapeutic results for ABVD and
OPP/ABVD as far as progression-free survival and
S were concerned. Both regimens were superior to
OPP. ABVD had less germ cell and hematopoietic
tem cell toxicity. A long-term follow-up of this study
ver 15 years has recently been published demonstrat-
ng a 45% to 50% progression-free survival and a 65%
verall survival for ABVD and MOPP/ABVD [31].
There are single-center reports with more favor-
ble results using ABVD, MOPP/ABV (adriamycin,
leomycin, vincristine), or similar regimens, but the
umbers of patients are small and seem to carry a bias
f selection.
These rather disappointing results raised a num-
er of questions:
. Is ABVD good enough, with 30% to 35% failures
within 5 to 10 years?
. How can we improve initial tumor control without
compromising long-term cure?
. Do we need consolidating radiotherapy after effective
chemotherapy?
. Are the fourth-generation regimens Stanford V, bleomycin,
etoposide, adriamycin, cyclophosphamide, oncovin [vincristine],
procarbazine, prednisone (BEACOPP), chlorambucil, vin-
blastine, procarbazine, prednisone, etoposide, vincristine
(ChlVPP/EVA), and mechlorethamine (MEC) better than
ABVD, both short and long term? h
B & M T. How can we improve the quality and quantity of life by
reducing acute and long-term toxicity?
These questions led the GHSG in 1992 to inves-
igate a new principle on the basis of the cyclophos-
hamide, vincristine (Oncovin), procarbazine, pred-
isone (COPP)/ABVD regimen by using the same
rugs, except for dacarbazine and vinblastine, adding
toposide, and introducing a time- and dose-escalated
chedule in lymphoma treatment for the ﬁrst time,
hus formulating the BEACOPP principle (Table 2).
his regimen allows administration of the most tu-
oricidal drugs on day 1 to 3 and recycling on day 21
nstead on day 28—or, in the BEACOPP-14 regimen,
n day 15—and, by the help of granulocyte colony-
timulating factor (G-CSF), to escalate the dosage
f etoposide, cyclophosphamide, and doxorubicin by
00%, approximately 90%, and approximately 40%, re-
pectively.
In a randomized 3-arm phase III study, COPP/
BVD was tested against baseline BEACOPP and
scalated BEACOPP. Radiotherapy in this study was
iven to initial bulk and residual tumors with 30 Gy in
pproximately 65% to 70% of patients [32].
At the last analysis in June 2003, after a median
ollow-up of 7 years, the escalated BEACOPP arm
howed highly signiﬁcant superiority over the COPP/
BVD arm for FFTF (85% versus 67%; P  .0001)
nd OS (90% versus 79%; P  .0001), despite the
able 2. BEACOPP Regimens
Regimen
EACOPP (baseline) 21
Bleomycin 10 IV 8
Etoposide 100 IV 1-3
Adriamycin (doxorubicin) 25 IV 1
Cyclophosphamide 650 IV 1
Oncovin (vincristine) 1.4* IV 8
Procarbazine 100 PO 1-7
Prednisone 40 PO 1-14
EACOPP (escalated) 21
Bleomycin 10 IV 8
Etoposide 200 IV 1-3
Adriamycin (doxorubicin) 35 IV
Cyclophosphamide 1250 IV 1
Oncovin (vincristine) 1.4* IV 8
Procarbazine 100 PO 1-7
Prednisone 40 PO 1-14
G-CSF  SQ 8
EACOPP-14 14
Bleomycin 10 IV 8
Etoposide 100 IV 1-3
Adriamycin (doxorubicin) 25 IV
Cyclophosphamide 650 IV 1
Oncovin (vincristine) 1.4* IV 8
Procarbazine 100 PO 1-7
Prednisone 40 PO 1-7
G-CSF  SQ 8-13
V indicates intravenous; PO, by mouth; SQ, subcutaneously;
G-CSF, granulocyte colony-stimulating factor.
Vincristine dose capped at 2 mg.igher number of 11 acute myeloid leukemia (AML)/
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7yelodysplastic syndrome patients in the BEACOPP
scalated arm versus 1 in the COPP/ABVD arm.
owever, the death rate due to progression of HD
as 9.6% in the COPP/BVD arm and only 2.4% in
he BEACOPP escalated group of patients. Further-
ore, there was no survival difference after salvage
reatment among the 3 treatment arms.
However, the superiority of 8 cycles of escalated
EACOPP over the former standard-arm COPP/
BVD had the prize of a considerably higher acute
nd late toxicity. Therefore, the GHSG started to
ndertake 2 successive studies, HD12 and HD15 (Fig-
res 1 and 2), to de-escalate BEACOPP and reduce
adiotherapy, hence reducing the toxic burden of this
ery effective principle.
In the HD12 study, 8 cycles of escalated BEA-
OPP were compared with 4 cycles of escalated and 4
ycles of baseline BEACOPP, and by following a fac-
orial design, there was a further randomization for
adiotherapy (yes or no). A total of 65% of patients
n the radiotherapy arms received 30 Gy of IFRT,
hereas in the nonradiotherapy arms, 10% were ra-
iated because of the decision of a panel that, inde-
endently of the randomization, judged every CT
fter the end of chemotherapy.
In the second interim analysis in June 2004, 1396
atients were evaluable. After a median follow-up of 2
ears in this sequential analysis, there was neither a
ifference among the 8 BEACOPP escalated and 4
EACOPP escalated  4 BEACOPP baseline arms
or a difference for the radiotherapy (yes and no)
rms, either for FFTF or OS. At a median follow-up
f 30 months, the FFTF for the total cohort was
6.9%, and the OS was 93.8%. At this time of obser-
ation, the rate for AML/myelodysplastic syndrome
as only half of that observed in the HD9 trial at the
ame time point. These results favor the continuation
igure 1. HD12 study design of the GHSG for patients with
dvanced Hodgkin’s disease. RT indicates radiotherapy.f the global study, chaired by Dr. Patrice Cadre from e
2he EORTC, comparing ABVD with BEACOPP (4
) with or without radiotherapy.
In conclusion, ABVD is not generally accepted
orldwide as the gold standard chemotherapy regi-
en for advanced stages of Hodgkin lymphoma,
hereas it is the most favored regimen for early and
ntermediate stages of Hodgkin lymphoma. The new
eneration of dose-intensiﬁed or dose-dense chemo-
herapy regimens such as BEACOPP have to be tested
n different cultural and health structure settings to
rove their expected superiority over conventional
chemes, such as ABVD or MOPP/ABV, to improve
he long-term quantity and quality of life of Hodgkin
ymphoma patients. The role of consolidating radio-
herapy after reaching clinically conﬁrmed, CT/mag-
etic resonance–conﬁrmed, or PET-conﬁrmed CR
as to be assessed in ongoing studies, eg, the HD15
tudy of the GHSG.
rognostic Factors in Relapsed and Refractory HD
It was ﬁrst noted in 1979 that the length of
emission to ﬁrst-line chemotherapy had a marked
ffect on the ability of patients to respond to sub-
equent salvage treatment [33]. In 1992, the Na-
ional Cancer Institute updated their experience
ith the long-term follow-up of patients who re-
apsed after polychemotherapy [34]. Derived pri-
arily from investigations involving failures after
OPP and MOPP variants, the conclusions are
hought to be relevant to other chemotherapy pro-
rams as well. On this basis, chemotherapy failures
an be divided into 3 subgroups:
. Primary progressive HD, ie, patients who never achieve
a CR.
. Early relapses within 12 months of CR.
. Late relapses after CR lasting 12 months.
With use of conventional chemotherapy for pa-
igure 2. HD15 study of the GHSG for patients with advanced
odgkin’s disease. RT indicates radiotherapy. EPO  Erythropoi-tin.
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Advances in Hodgkin Disease
Bients with primary progressive disease, virtually no
atient survives 8 years. In contrast, the projected
0-year survival for patients with early relapse or late
elapse was 11% and 22%, respectively [34].
rimary Progressive HD
The GHSG retrospectively analyzed 206 patients
ith progressive disease, deﬁned as progression dur-
ng induction treatment or within 90 days after the
nd of treatment, to determine outcome after salvage
herapy and to identify prognostic factors [35]. The
-year freedom from second failure (FF2F) and OS
or all patients were 17% and 26%, respectively. As
eported from transplant centers, the 5-year FF2F and
S for patients treated with high-dose chemotherapy
HDCT) are 42% and 48%, respectively, but only
3% of all patients received HDCT. The low per-
entage of patients who received HDCT was due to
apidly fatal disease or life-threatening severe toxicity
fter salvage therapy. Other reasons not to proceed to
DCT were an insufﬁcient stem cell harvest, poor
erformance status, and older age. In a multivariate
nalysis, Karnofsky performance score at progression
P  .0001), age (P  .019), and attainment of a
emporary remission to ﬁrst-line chemotherapy (P 
0003) were signiﬁcant prognostic factors for survival.
atients with none of these risk factors had a 5-year
S of 55%, compared with 0% for patients with all 3
f these unfavorable prognostic factors.
arly and Late Relapsed HD
Although the results reported with HDCT in pa-
ients with late relapse have been superior to those
eported in most series of conventional chemotherapy,
he use of HDCT in late relapses had been an area of
ontroversy because patients with late relapse have
atisfactory second CR rates when treated with con-
entional chemotherapy, with OS ranging from 40%
o 55%. However, the HDR-1 trial of the GHSG also
howed improved FFTF after HDCT compared with
onventional chemotherapy in patients with late re-
apse.
The GHSG has recently performed a retrospec-
ive analysis including a much larger number of re-
apsed patients (n  422) than previously reported.
he analysis of prognostic factors suggests that the
rognosis of a patient with relapsed HD can be esti-
ated according to several factors. The most relevant
actors were combined into a prognostic score. This
core was calculated on the basis of the duration of
rst remission, the stage at relapse, and the presence
r absence of anemia at relapse. Early recurrence
ithin 3 to 12 months after the end of primary treat-
ent, relapse stage III or IV, and hemoglobin 10.5
/dL in female or 12 g/dL in male patients contrib-
te to a score with possible values of 0, 1, 2, and 3, in a
B & M Trder of worsening prognosis [36]. This prognostic
core allows distinguishing patients with different
F2F and OS. The actuarial 4-year FF2F and OS for
atients relapsing after chemotherapy with 3 unfavor-
ble factors were 17% and 27%, respectively. In con-
rast, patients with none of the unfavorable factors had
F2F and OS at 4 years of 48% and 83%, respectively.
n addition, the prognostic score was also predictive
or patients who relapsed after radiotherapy, for patients
ho relapsed after chemotherapy who were treated with
onventional therapies or with HDCT followed by au-
ologous stem cell transplantation (ASCT), and for pa-
ients 60 years and a Karnofsky performance status
90%, which were the major candidate groups for
ose intensiﬁcation. The prognostic factor score uses
linical characteristics that can be easily collected at
he time of relapse. It separates groups of patients with
ubstantially different outcomes.
reatment Strategies
Patients who relapse after radiation therapy alone
or localized HD have satisfactory results with com-
ination chemotherapy and are not considered candi-
ates for HDCT and ASCT [12,13]. HDCT followed
y ASCT has been shown to produce 30% to 65%
ong-term disease-free survival in selected patients
ith refractory and relapsed HD. In addition, the
eduction of early transplant-related mortality from
he 10% to 25% reported in earlier studies to 5% in
ore recent studies has led to the widespread accep-
ance of HDCT and ASCT.
Although results of HDCT have generally been
etter than those observed after conventional-dose
alvage therapy, the validity of these results has been
uestioned because of the lack of randomized trials.
he most compelling evidence for the superiority of
DCT and ASCT in relapsed HD comes from 2 re-
orts from the British National Lymphoma Investiga-
ion and the GHSG, together with the European Group
or Blood and Marrow Transplantation (EBMT).
In the British National Lymphoma Investigation
rial, patients with relapsed or refractory HD were
reated with a combination of carmustine (BCNU),
toposide, cytarabine, and melphalan at a conven-
ional dose level (mini-BEAM) or a high-dose level
BEAM) with autologous bone marrow transplanta-
ion [37]. The actuarial 3-year event-free survival was
igniﬁcantly better in patients who received HDCT
53% versus 10%).
The largest randomized, multicenter trial was per-
ormed by the GHSG/EBMT to determine the beneﬁt
f HDCT in relapsed HD. Patients with relapse after
olychemotherapy were randomly assigned between 4
ycles of dexa-BEAM (dexamethasone  BEAM) and
cycles of dexa-BEAM followed by HDCT (BEAM)nd autologous bone marrow transplantation/periph-
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7ral blood stem cell transplantation (PBSCT). The
nal analysis of 144 evaluable patients revealed that of
17 patients with partial remission (PR) or CR after 2
ycles of chemotherapy, FFTF in the HDCT group
as 55%, versus 34% for the patients who received an
dditional 2 cycles of chemotherapy. OS was not sig-
iﬁcantly different [38].
equential HDCT
In recent years, sequential HDCT has increas-
ngly been used in the treatment of solid tumors and
ematologic and lymphoproliferative disorders. Initial
esults from phase I/II studies indicate that this kind of
herapy offers safe and effective treatment. In accor-
ance with the Norton-Simon hypothesis, after initial
ytoreduction, few non–cross-resistant agents are given
t short intervals. In general, PBSCT and the use of
rowth factors allow the application of the most effec-
ive drugs at the highest possible doses at intervals of
to 3 weeks. Sequential HDCT thereby enables the
ighest possible dosing over a minimum period of
ime (dose intensiﬁcation).
In 1997, a multicenter phase II trial with a high-
ose sequential chemotherapy program and a ﬁnal
yeloablative course was started to evaluate the fea-
ibility and efﬁcacy of this novel regimen in patients
ith relapsed HD [26]. Eligibility criteria included
ge 18 to 60 years, histologically proven relapsed or
rimary progressive HD, second relapse with no prior
DCT, and an Eastern Cooperative Oncology Group
erformance status of 0 or 1. The treatment program
onsists of 2 cycles of DHAP (dexamethasone, cytar-
bine, and cisplatin) in the ﬁrst phase to reduce the
umor burden before HDCT. Patients with PR or CR
fter 2 cycles of DHAP receive sequential HDCT
onsisting of cyclophosphamide 4 g/m2 intravenously
IV), methotrexate 8 g/m2 IV plus vincristine 1.4
g/m2 IV, and etoposide 2 g/m2 IV. The ﬁnal my-
loablative course was BEAM followed by PBSCT
ith at least 2  106 CD34 cells per kilogram [39].
At the last interim analysis, 102 patients were
vailable for the ﬁnal evaluation. The state of remis-
ion was multiple relapses in 10 patients, progressive
isease in 16 patients, early relapse in 29 patients, and
ate relapse in 44 patients. At 30 months of median
ollow-up (range, 3-61 months), results are as follows:
esponse rate after DHAP, 87% (23% CR and 64%
R); response rate at ﬁnal evaluation, 77% (68% CR
nd 9% PR). Toxicity was tolerable, with no treat-
ent-related deaths. FFTF and OS for patients with
arly relapse were 64% and 87%, respectively, for
arly relapse; 68% and 81% for late relapse; 30% and
8% for patients with progressive disease; and 55%
nd 88% for patients with multiple relapses [40].
In conclusion, sequential administration of high
oses of cyclophosphamide, methotrexate, and etopo- g
4ide is feasible and did not affect the tolerability of
nal myeloablative BEAM. This new 3-phase treat-
ent regimen is well tolerated and feasible in patients
ith relapsed and primary progressive HD. The pre-
iminary data suggest a high efﬁcacy in relapsed HD
atients; thus, further randomized studies are war-
anted.
DR-2 Protocol
In January 2001, the GHSG, together with the
ORTC, the GEL/TAMO, and the EBMT, started a
rospective randomized study to compare the effec-
iveness of standard HDCT (BEAM) with sequential
DCT after initial cytoreduction with 2 cycles of
HAP (HD-R2 protocol; Figure 3). Patients with
istologically conﬁrmed early or late relapsed HD and
atients in second relapse with no prior HDCT ful-
lling the entry criteria receive 2 cycles of DHAP
ollowed by G-CSF.
Patients who achieve no change in their disease sta-
us, a PR, or a CR after DHAP are centrally randomized
o receive either BEAM followed by PBSCT (arm A of
he study) or high-dose cyclophosphamide  G-CSF,
ollowed by high-dose methotrexate  vincristine, fol-
owed by high-dose etoposide  G-CSF and a ﬁnal
yeloablative course with BEAM (arm B of the study).
llogeneic Transplantation after Reduced
onditioning in HD
Allogeneic transplantation (alloBMT) has clear
dvantages compared with autologous transplantation:
onor marrow cells uninvolved by malignancy are
sed, thus avoiding the risk of infusing occult lym-
homa cells, which may contribute to relapse in pa-
ients who undergo autologous transplantation. In ad-
ition, donor lymphoid cells can potentially mediate a
igure 3. HDR-2: study design (GHSG, EORTC, EBMT, and
EL/TAMO). CTX indicates cyclophosphamide, MTX, metho-
rexate; VP-16, etoposide.raft-versus-lymphoma effect.
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Advances in Hodgkin Disease
BGenerally, donor availability and age constraints
ave limited a broader application of alloBMT in HD.
oreover, alloBMT is associated with a high treat-
ent-related mortality rate of up to 75% in patients
ith induction failure, which casts doubt upon the
easibility of this approach in HD patients. In most
ases, alloBMT from HLA-identical siblings is not
ecommended for patients with HD. The reduced
elapse rate associated with a potential graft-versus-
umor effect is offset by lethal graft-versus-host tox-
city.
Nevertheless, patients with induction failure and
elapsed patients with additional risk factors also have
poor prognosis after HDCT and ASCT. Therefore,
he role of alloBMT should be further evaluated in
hese patients by taking advantage of new develop-
ents such as nonmyeloablative conditioning regi-
ens and allogeneic PBSCT.
To circumvent the problems inherent to the tox-
city and treatment-related mortality associated with
llografting, the possibility of achieving engraftment
f allogeneic stem cells after immunosuppressive ther-
py combined with myelosuppressive but nonmyeloa-
lative therapy has been assessed. Several groups have
ecently updated their experience with nonmyeloab-
ative conditioning regimens [40].
The EBMT, together with the GEL/TAMO, the
ORTC, and the GHSG, activated a multicenter
hase II study to evaluate the treatment-related mor-
ality of patients with primary progressive or relapsed
D (early relapse, multiple relapse, and relapse after
SCT). Patients with an HLA-compatible sibling do-
or or an HLA-matched unrelated donor will be ini-
ially treated with 1 or 2 cycles of DHAP or other
alvage protocols to reduce their tumor burden before
llogeneic PBSCT. PBSCs will be collected after
-CSF priming of the donor and reinfused after con-
itioning with ﬂudarabine and melphalan.
UTURE DIRECTIONS
Alternative strategies have been developed to im-
rove the outcome of relapsed and resistant HD. These
pproaches include the development of new cytostatic
rugs and biological agents with proven efﬁcacy in pre-
linical models.
One of the most promising new cytostatic drugs is
he new vinca alkaloid vinorelbine, which has demon-
trated activity in HD even in patients pretreated with
incristine or vinblastine. The use of vinorelbine in
rst- and second-line therapy of HD to improve the
requency and duration of responses is still under
nvestigation. The pyrimidine analogue gemcitabine is
he only drug currently under investigation that rep-
esents a new cytostatic mechanism of action. The
self-potentiating” mechanism of action leads to an
B & M Tnhanced accumulation and prolonged retention of
emcitabine in the malignant cell. The results of gem-
itabine in advanced relapsed HD are promising, with
n overall response rate of 53% in heavily pretreated
atients.
Although some clinical efﬁcacy has been demon-
trated in clinical trials with immunotoxins, none of
he current available immunotoxins seems to be suited
or a clinical phase III study. Bispeciﬁc monoclonal
ntibodies, such as the recently reported CD30 
D64 bispeciﬁc monoclonal antibodies, look more
romising, with clinical development programs sched-
led that include phase III. The use of recombinant
NA technology for site-directed modiﬁcations of
he immunotoxins and the development of humanized
mmunotoxins and bispeciﬁc monoclonal antibodies
ight optimize their efﬁcacy. In the future, combin-
ng standard chemotherapy/radiotherapy with biolog-
cal agents might result in the elimination of residual
umor cells and, subsequently, more relapse-free long-
erm survivors.
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